| HOME >> MEDICINE >> TECHNOLOGY |
About Human Genome Sciences
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing. ABthrax(TM) (raxibacumab) is in late-stage development for inhalation anthrax, and HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, which GSK has advanced to Phase 3 development as a potential treatment for coronary heart disease.
For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.
For an Electronic Press Kit on this announcement, please click here: http://www.firstlinemedia.com/epk/hgs/.
HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B ar
'/>"/>
| SOURCE Human Genome Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved |